Vitamin B6 for those with hand-foot syndrome

Study performed in dogs (clinical trial currently recruiting in humans), but as any excess B6 taken will only be excreted by the kidneys, why not try it?:


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
This Article

Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted

Services

Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Cited by other online articles

Google Scholar

Articles by Vail, D. M.
Articles by Obradovich, J. E.
Articles citing this Article

PubMed

PubMed Citation
Articles by Vail, D. M.
Articles by Obradovich, J. E.
Clinical Cancer Research, Vol 4, Issue 6 1567-1571, Copyright © 1998 by American Association for Cancer Research

ARTICLES


Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model

DM Vail, R Chun, DH Thamm, LD Garrett, AJ Cooley and JE Obradovich
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison 53706, USA. vaild@svm.vetmed.wisc.edu

A cutaneous reaction termed palmar-plantar erythrodysesthesia (PPES) or hand-foot syndrome can be dose limiting for Doxil, a doxorubicin containing pegylated (Stealth) liposome. The objective of this study was to determine the ability of concomitant pyridoxine therapy to prevent the development of PPES during Doxil therapy. Forty-one dogs with non-Hodgkin's lymphoma were randomized in a double-blind fashion to receive either oral pyridoxine or placebo daily during Doxil chemotherapy (1.0 mg/kg, i.v., every 3 weeks for a total of five treatments). Cutaneous toxicity was determined by clinical and histological scoring. No difference was observed in remission rates (71.4 versus 75%) achieved between groups. The likelihood of developing serious PPES and having to decrease or discontinue Doxil therapy was 4.2 times (relative risk) greater in placebo group dogs than in pyridoxine group dogs (P = 0.032). Pyridoxine did not completely abrogate PPES; however, it occurred later and less dramatically than in placebo-treated dogs and resulted in fewer treatment delays or discontinuations, allowing a higher cumulative dose of Doxil to be received. Compared to the 5.0 mg/kg cumulative target dose, pyridoxine-treated dogs received a median cumulative dose of 4.7 mg/kg (mean, 4.1 mg/kg), and the placebo-treated dogs received a median of 2.75 mg/kg (mean, 2.9 mg/kg; P < 0.028). A trend (P = 0.084) toward prolongation of remission length was observed in dogs receiving pyridoxine, which was likely attributable to their ability to receive more Doxil without delay or discontinuation. We conclude that pyridoxine is effective in delaying the onset and severity of PPES in this canine model.